Nusaibah Abdul Rahim1, Soon-Ee Cheah1, Matthew D Johnson1, Heidi Yu1, Hanna E Sidjabat2, John Boyce3, Mark S Butler4, Matthew A Cooper4, Jing Fu5, David L Paterson6, Roger L Nation1, Phillip J Bergen7, Tony Velkov1, Jian Li8. 1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia. 2. University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia. 3. Department of Microbiology, Monash University, Melbourne, Victoria, Australia. 4. Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia. 5. Department of Mechanical and Aerospace Engineering, Faculty of Engineering, Monash University, Clayton, Victoria, Australia. 6. University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia Pathology Queensland, Royal Brisbane and Women's Hospital Campus, Brisbane, Queensland, Australia. 7. Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia. 8. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia colistin.polymyxin@gmail.com.
Abstract
OBJECTIVES: Combination therapy is an important option in the fight against Gram-negative 'superbugs'. This study systematically investigated bacterial killing and the emergence of polymyxin resistance with polymyxin B and chloramphenicol combinations used against New Delhi metallo-β-lactamase (NDM)-producing MDR Klebsiella pneumoniae. METHODS: Four NDM-producing K. pneumoniae strains were employed. The presence of genes conferring resistance to chloramphenicol was examined by PCR. Time-kill studies (inocula ∼10(6) cfu/mL) were conducted using various clinically achievable concentrations of each antibiotic (range: polymyxin B, 0.5-2 mg/L; chloramphenicol, 4-32 mg/L), with real-time population analysis profiles documented at baseline and 24 h. The microbiological response was examined using the log change method and pharmacodynamic modelling in conjunction with scanning electron microscopy (SEM). RESULTS: Multiple genes coding for efflux pumps involved in chloramphenicol resistance were present in all strains. Polymyxin B monotherapy at all concentrations produced rapid bacterial killing followed by rapid regrowth with the emergence of polymyxin resistance; chloramphenicol monotherapy was largely ineffective. Combination therapy significantly delayed regrowth, with synergy observed in 25 out of 28 cases at both 6 and 24 h; at 24 h, no viable bacterial cells were detected in 15 out of 28 cases with various combinations across all strains. No polymyxin-resistant bacteria were detected with combination therapy. These results were supported by pharmacodynamic modelling. SEM revealed significant morphological changes following treatment with polymyxin B both alone and in combination. CONCLUSIONS: The combination of polymyxin B and chloramphenicol used against NDM-producing MDR K. pneumoniae substantially enhanced bacterial killing and suppressed the emergence of polymyxin resistance.
OBJECTIVES: Combination therapy is an important option in the fight against Gram-negative 'superbugs'. This study systematically investigated bacterial killing and the emergence of polymyxin resistance with polymyxin B and chloramphenicol combinations used against New Delhi metallo-β-lactamase (NDM)-producing MDR Klebsiella pneumoniae. METHODS: Four NDM-producing K. pneumoniae strains were employed. The presence of genes conferring resistance to chloramphenicol was examined by PCR. Time-kill studies (inocula ∼10(6) cfu/mL) were conducted using various clinically achievable concentrations of each antibiotic (range: polymyxin B, 0.5-2 mg/L; chloramphenicol, 4-32 mg/L), with real-time population analysis profiles documented at baseline and 24 h. The microbiological response was examined using the log change method and pharmacodynamic modelling in conjunction with scanning electron microscopy (SEM). RESULTS: Multiple genes coding for efflux pumps involved in chloramphenicol resistance were present in all strains. Polymyxin B monotherapy at all concentrations produced rapid bacterial killing followed by rapid regrowth with the emergence of polymyxin resistance; chloramphenicol monotherapy was largely ineffective. Combination therapy significantly delayed regrowth, with synergy observed in 25 out of 28 cases at both 6 and 24 h; at 24 h, no viable bacterial cells were detected in 15 out of 28 cases with various combinations across all strains. No polymyxin-resistant bacteria were detected with combination therapy. These results were supported by pharmacodynamic modelling. SEM revealed significant morphological changes following treatment with polymyxin B both alone and in combination. CONCLUSIONS: The combination of polymyxin B and chloramphenicol used against NDM-producing MDR K. pneumoniae substantially enhanced bacterial killing and suppressed the emergence of polymyxin resistance.
Authors: Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki Journal: Clin Infect Dis Date: 2013-05-22 Impact factor: 9.079
Authors: Thidarat Netikul; Hanna E Sidjabat; David L Paterson; Witchuda Kamolvit; Woraphot Tantisiriwat; Jason A Steen; Pattarachai Kiratisin Journal: J Antimicrob Chemother Date: 2014-08-04 Impact factor: 5.790
Authors: S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation Journal: Antimicrob Agents Chemother Date: 2011-05-09 Impact factor: 5.191
Authors: Rajnikant Sharma; Saloni Patel; Cely Abboud; John Diep; Neang S Ly; Jason M Pogue; Keith S Kaye; Jian Li; Gauri G Rao Journal: Int J Antimicrob Agents Date: 2016-12-23 Impact factor: 5.283
Authors: Thien B Tran; Tony Velkov; Roger L Nation; Alan Forrest; Brian T Tsuji; Phillip J Bergen; Jian Li Journal: Int J Antimicrob Agents Date: 2016-10-18 Impact factor: 5.283
Authors: Elena K Schneider; Mohammad A K Azad; Mei-Ling Han; Qi Tony Zhou; Jiping Wang; Johnny X Huang; Matthew A Cooper; Yohei Doi; Mark A Baker; Phillip J Bergen; Mark T Muller; Jian Li; Tony Velkov Journal: ACS Infect Dis Date: 2016-05-17 Impact factor: 5.084
Authors: Rajbharan Yadav; Jürgen B Bulitta; Elena K Schneider; Beom Soo Shin; Tony Velkov; Roger L Nation; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2017-11-22 Impact factor: 5.191